

VEGF-C (C-20): sc-1881



The Power to Question

BACKGROUND

The onset of angiogenesis is believed to be an early event in tumorigenesis and may facilitate tumor progression and metastasis. Several growth factors with angiogenic activity have been described. These include fibroblast growth factor (FGF), platelet derived growth factor (PDGF) and vascular endothelial growth factor (VEGF). VEGF is a dimeric glycoprotein with structural homology to PDGF. Several variants of VEGF have been described that arise by alternative mRNA splicing. It has been speculated that VEGF may function as a tumor angiogenesis factor *in vivo*. Two additional proteins designated VEGF-B and VEGF-C share a significant degree of homology with VEGF. VEGF-B is abundantly expressed in heart and skeletal muscle and is frequently co-expressed with VEGF. VEGF-C binds to and specifically activates Flt-4 and Flk-1. The genes that encode VEGF-B and VEGF-C have been localized to chromosomes 11q13.1 and 4q34.3, respectively.

CHROMOSOMAL LOCATION

Genetic locus: VEGFC (human) mapping to 4q34.3; Vegfc (mouse) mapping to 8 B1.3.

SOURCE

VEGF-C (C-20) is an affinity purified goat polyclonal antibody raised against a peptide mapping at the C-terminus of VEGF-C of human origin.

PRODUCT

Each vial contains 200 µg IgG in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

Blocking peptide available for competition studies, sc-1881 P, (100 µg peptide in 0.5 ml PBS containing < 0.1% sodium azide and 0.2% BSA).

APPLICATIONS

VEGF-C (C-20) is recommended for detection of VEGF-C precursor of mouse, rat and human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunoprecipitation [1-2 µg per 100-500 µg of total protein (1 ml of cell lysate)], immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000).

VEGF-C (C-20) is also recommended for detection of VEGF-C precursor in additional species, including canine and porcine.

Suitable for use as control antibody for VEGF-C siRNA (h): sc-39842, VEGF-C siRNA (m): sc-39843, VEGF-C shRNA Plasmid (h): sc-39842-SH, VEGF-C shRNA Plasmid (m): sc-39843-SH, VEGF-C shRNA (h) Lentiviral Particles: sc-39842-V and VEGF-C shRNA (m) Lentiviral Particles: sc-39843-V.

Molecular Weight of VEGF-C: 40/80 kDa.

Positive Controls: MH-S whole cell lysate, mouse brain extract: sc-2253 or MCF7 whole cell lysate: sc-2206.


STORAGE

Store at 4° C, **DO NOT FREEZE**. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.


RESEARCH USE

For research use only, not for use in diagnostic procedures.

DATA



VEGF-C (C-20): sc-1881. Western blot analysis of VEGF-C expression in MH-S whole cell lysate (A) and mouse brain tissue extract (B).



VEGF-C (C-20): sc-1881. Immunofluorescence staining of methanol-fixed RAW 264.7 cells showing cytoplasmic localization.

SELECT PRODUCT CITATIONS

- Bunone, G., et al. 1999. Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features. *Am. J. Pathol.* 155: 1967-1976.
- Brar, R., et al. 2009. Breast angiosarcoma: case series and expression of vascular endothelial growth factor. *Case Rep. Oncol.* 2: 242-250.
- Müller-Deile, J., et al. 2009. The balance of autocrine VEGF-A and VEGF-C determines podocyte survival. *Am. J. Physiol. Renal Physiol.* 297: F1656-F1667.
- Spinella, F., et al. 2009. Endothelin-1 stimulates lymphatic endothelial cells and lymphatic vessels to grow and invade. *Cancer Res.* 2009: 2669-2676.
- Kubo, M., et al. 2010. Extracorporeal shock wave therapy ameliorates secondary lymphedema by promoting lymphangiogenesis. *J. Vasc. Surg.* 52: 429-434.
- Gordon, E.J., et al. 2010. Macrophages define dermal lymphatic vessel calibre during development by regulating lymphatic endothelial cell proliferation. *Development* 137: 3899-3910.
- Moussai, D., et al. 2011. The human cutaneous squamous cell carcinoma microenvironment is characterized by increased lymphatic density and enhanced expression of macrophage-derived VEGF-C. *J. Invest. Dermatol.* 131: 229-236.
- Li, H., et al. 2011. Insulin-like growth factor-I receptor blockade reduces tumor angiogenesis and enhances the effects of bevacizumab for a human gastric cancer cell line, MKN45. *Cancer* 117: 3135-3147.
- Shimoda, H., et al. 2011. Dysmorphogenesis of lymph nodes in Foxc2 haploinsufficient mice. *Histochem. Cell Biol.* 135: 603-613.

MONOS
Satisfaction
Guaranteed

Try **VEGF-C (E-6): sc-374628** or **VEGF-C (F-10): sc-74585**, our highly recommended monoclonal alternatives to VEGF-C (C-20). Also, for AC, HRP, FITC, PE, Alexa Fluor® 488 and Alexa Fluor® 647 conjugates, see **VEGF-C (E-6): sc-374628**.